
    
The genomic variant c.4423G>A p.Gly1475Arg rs796053216 on the SCN8A gene has been associated with a spectrum of neurological phenotypes, particularly epilepsy and intellectual disability (IDD). This missense mutation results in the substitution of glycine with arginine at the 1475th amino acid position of the protein encoded by SCN8A [1]. The SCN8A gene encodes the voltage-gated sodium-channel type VIII alpha subunit (NaV1.6), which plays a critical role in the generation and propagation of action potentials in neurons [6].The variant has been identified in patients presenting with epilepsy and IDD, with some individuals experiencing clusters of seizures followed by regression of developmental milestones [1]. The clinical presentation of individuals with this variant can vary, but SCN8A mutations are often associated with moderate-to-severe IDD and/or autistic traits [1]. The Gly1475Arg variant has been reported in multiple cases, suggesting that it may be a recurrent mutation [8]. Moreover, the variant has been observed in patients who presented with an intermediate SCN8A-related epilepsy with mild cognitive impairment, which in the majority is a treatable epilepsy [8].The functional implications of the Gly1475Arg variant are significant, as the SCN8A gene product is critical for the proper functioning of neuronal circuits. NaV1.6 channels are highly expressed in the central nervous system, particularly in the nodes of Ranvier of myelinated axons and the axon initial segments (AIS), where they are essential for the initiation of action potentials [6]. Mutations in SCN8A can lead to alterations in channel function, which can manifest as various neurological disorders, including epilepsy. The Gly1475Arg variant is located in a domain that is important for the inactivation of the channel, which is a crucial aspect of channel function and neuronal excitability [9].The c.4423G>A p.Gly1475Arg variant has been classified as pathogenic in ClinVar, with multiple submissions supporting this classification. This evidence, combined with the clinical data from patients and the critical role of SCN8A in neuronal function, underscores the importance of this variant in the pathogenesis of SCN8A-related disorders.

SCN8A遺伝子のゲノム変異c.4423G>A p.Gly1475Arg rs796053216は、特にてんかんや知的障害（IDD）を含む神経学的表現型のスペクトラムと関連付けられています。このミスセンス変異は、SCN8Aによってコードされるタンパク質の1475番目のアミノ酸位置でグリシンがアルギニンに置換される結果をもたらします[1]。SCN8A遺伝子は電位依存性ナトリウムチャネル型VIIIアルファサブユニット（NaV1.6）をコードしており、ニューロンにおける活動電位の生成と伝播に重要な役割を果たします[6]。この変異は、てんかんとIDDを呈する患者で確認されており、一部の患者では発作のクラスターが発生し、その後発達のマイルストーンの退行が見られることがあります[1]。この変異を持つ個人の臨床的な表現型は多様ですが、SCN8A変異は中等度から重度のIDDや自閉症的特徴と関連することが多いです[1]。Gly1475Arg変異は複数の症例で報告されており、再発性変異である可能性が示唆されています[8]。さらに、この変異は軽度の認知障害を伴う中間型のSCN8A関連てんかんを呈する患者で観察されており、大部分が治療可能なてんかんであることが報告されています[8]。

Gly1475Arg変異の機能的影響は重要であり、SCN8A遺伝子産物は神経回路の適切な機能に不可欠です。NaV1.6チャネルは中枢神経系で高度に発現しており、特に髄鞘化された軸索のランビエ絞輪や軸索初節（AIS）において、活動電位の開始に必要不可欠です[6]。SCN8Aの変異はチャネル機能の変化を引き起こし、てんかんを含むさまざまな神経学的障害として現れる可能性があります。Gly1475Arg変異はチャネルの不活性化に重要なドメインに位置しており、これはチャネル機能とニューロンの興奮性において重要な側面です[9]。

c.4423G>A p.Gly1475Arg変異はClinVarで病原性として分類されており、複数の提出がこの分類を支持しています。この証拠は、患者の臨床データとSCN8Aの神経機能における重要な役割と相まって、SCN8A関連障害の病因におけるこの変異の重要性を強調しています。
    
## References
- [1] Viswanathan LG et al. (2023). "Phenotypic features of epilepsy due to sodium channelopathies - A single center experience from India." Journal of neurosciences in rural practice, 14(4) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38059254/)
- [2] Wengert ER et al. (2021). "The Role of the Persistent Sodium Current in Epilepsy." Epilepsy currents, 21(1) [PubMed](https://pubmed.ncbi.nlm.nih.gov/33236643/)
- [3] Negi S et al. (2023). "Exploring the genetic landscape of diphtheria, tetanus and pertussis vaccination-associated seizures or subsequent epilepsies." The Lancet regional health. Southeast Asia, 8() [PubMed](https://pubmed.ncbi.nlm.nih.gov/37384142/)
- [4] Jang SS et al. (2019). "Diagnostic Yield of Epilepsy Panel Testing in Patients With Seizure Onset Within the First Year of Life." Frontiers in neurology, 10() [PubMed](https://pubmed.ncbi.nlm.nih.gov/31572294/)
- [5] Zaman T et al. (2019). "A single-center SCN8A-related epilepsy cohort: clinical, genetic, and physiologic characterization." Annals of clinical and translational neurology, 6(8) [PubMed](https://pubmed.ncbi.nlm.nih.gov/31402610/)
- [6] Menezes LFS et al. (2020). "Epilepsy-Related Voltage-Gated Sodium Channelopathies: A Review." Frontiers in pharmacology, 11() [PubMed](https://pubmed.ncbi.nlm.nih.gov/33013363/)
- [7] Wang J et al. (2017). "SCN8A mutations in Chinese patients with early onset epileptic encephalopathy and benign infantile seizures." BMC medical genetics, 18(1) [PubMed](https://pubmed.ncbi.nlm.nih.gov/28923014/)
- [8] Johannesen KM et al. (2019). "The spectrum of intermediate SCN8A-related epilepsy." Epilepsia, 60(5) [PubMed](https://pubmed.ncbi.nlm.nih.gov/30968951/)
- [9] Xiao Y et al. (2018). "Early-onset epileptic encephalopathy with de novo SCN8A mutation." Epilepsy research, 139() [PubMed](https://pubmed.ncbi.nlm.nih.gov/29128679/)
- [10] Liu Y et al. (2019). "Neuronal mechanisms of mutations in SCN8A causing epilepsy or intellectual disability." Brain : a journal of neurology, 142(2) [PubMed](https://pubmed.ncbi.nlm.nih.gov/30615093/)
- [11] Bayraktar E et al. (2023). "In vitro effects of eslicarbazepine (S-licarbazepine) as a potential precision therapy on SCN8A variants causing neuropsychiatric disorders." British journal of pharmacology, 180(8) [PubMed](https://pubmed.ncbi.nlm.nih.gov/36321697/)
- [12] C. Galati et al. (2017). "A novel de novo SCN8A mutation in an Italian child treated with Levetiracetam: a case in discussion" , 2 [PubMed](https://doi.org/10.11138/ccre/2017.2.1.066)
- [13] Erva Bayraktar et al. (2021). "In vitro effects of S-Licarbazepine as a potential precision therapy on SCN8A variants causing neuropsychiatric disorders" bioRxiv,  [PubMed](https://doi.org/10.1101/2021.04.24.441205)
- [14] J. Magielski et al. (2024). "Deciphering the dynamic clinical patterns in SCN8A-related disorders using real-world data" ,  [PubMed](https://doi.org/10.1101/2024.10.21.24315870)
- [15] Hack JB et al. (2024). "Machine learning models reveal distinct disease subgroups and improve diagnostic and prognostic accuracy for individuals with pathogenic SCN8A gain-of-function variants." Biology open, 13(4) [PubMed](https://pubmed.ncbi.nlm.nih.gov/38466077/)

    
## ClinVar Submissions
- **[RCV000189277](https://www.ncbi.nlm.nih.gov/clinvar/RCV000189277/)**: not provided
- **[RCV000500598](https://www.ncbi.nlm.nih.gov/clinvar/RCV000500598/)**: Developmental and epileptic encephalopathy, 13
- **[RCV000462091](https://www.ncbi.nlm.nih.gov/clinvar/RCV000462091/)**: Early infantile epileptic encephalopathy with suppression bursts
- **[RCV000416962](https://www.ncbi.nlm.nih.gov/clinvar/RCV000416962/)**: Epileptic encephalopathy
- **[RCV000627041](https://www.ncbi.nlm.nih.gov/clinvar/RCV000627041/)**: Epilepsy
- **[RCV002037567](https://www.ncbi.nlm.nih.gov/clinvar/RCV002037567/)**: Early infantile epileptic encephalopathy with suppression bursts

    